NCT01536054.

Trial name or title	Sirolimus and vaccine therapy in treating patients with stage II‐IV ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer
Methods	Uncontrolled phase I
Participants	12 women with completed therapy for primary or recurrent disease with asymptomatic residual disease or complete remission
Interventions	Subcutaneous injections with ALVAC(2)‐NY‐ESO‐1 (M)/TRICOM vaccine, subcutaneous GM‐CSF, and oral sirolimus
Outcomes	Adverse events Immune responses Survival
Starting date	August 2012
Contact information
Notes	Active not recruiting, March 2017